| Product NDC: | 16729-078 |
| Proprietary Name: | CARBIDOPA AND LEVODOPA |
| Non Proprietary Name: | Carbidopa and Levodopa |
| Active Ingredient(s): | 25; 100 mg/1; mg/1 & nbsp; Carbidopa and Levodopa |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, EXTENDED RELEASE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 16729-078 |
| Labeler Name: | Accord Healthcare, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA202323 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20130509 |
| Package NDC: | 16729-078-16 |
| Package Description: | 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (16729-078-16) |
| NDC Code | 16729-078-16 |
| Proprietary Name | CARBIDOPA AND LEVODOPA |
| Package Description | 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (16729-078-16) |
| Product NDC | 16729-078 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Carbidopa and Levodopa |
| Dosage Form Name | TABLET, EXTENDED RELEASE |
| Route Name | ORAL |
| Start Marketing Date | 20130509 |
| Marketing Category Name | ANDA |
| Labeler Name | Accord Healthcare, Inc. |
| Substance Name | CARBIDOPA; LEVODOPA |
| Strength Number | 25; 100 |
| Strength Unit | mg/1; mg/1 |
| Pharmaceutical Classes | Aromatic Amino Acid Decarboxylation Inhibitor [EPC],DOPA Decarboxylase Inhibitors [MoA] |